Drug intelligence / Profile preview

Dapagliflozin + empagliflozin

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

This refers to a combination of two separate SGLT2 inhibitors, dapagliflozin (marketed under brand names like Farxiga) and empagliflozin (marketed under brand names like Jardiance). It is important to note that **this specific combination of dapagliflozin and empagliflozin is not available as a single approved or marketed pharmaceutical product.** Both drugs belong to the same class and have similar mechanisms of action, and thus would not typically be prescribed together.

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A11 (Sodium-coupled myo-inositol transporter 2 (SMIT2))SLC5A1 (Sodium Glucose Cotransporter 1)

Beyond the preview

Go deeper on Dapagliflozin + empagliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dapagliflozin + empagliflozin.

Explore the full profile